SEPTIN9 and colorectal carcinoma: We observed substantial differences between the CRC and healthy control groups at the SEPT9 promoter region, the current FDA-approved methylation biomarker for CRC [18] (Fig. 2a), suggesting that the LABS is capable of recapturing this established biomarker.